MWCapital incorporatesOneCareAI into its portfolio of companies

• OneCareAI is a spin-off using artificial intelligence to prevent strokes and reduce associated healthcare costs, which amount to $1 trillion globally every year
• The project originates from the Barcelona Supercomputing Centre and has been validated through MWCapital’s technology transfer programme

20/May/2025

Mobile World Capital Barcelona (MWCapital) has added OneCareAI to its portfolio of companies in its technology transfer programme. This new spin-off, emerging from the Barcelona Supercomputing Centre – Centro Nacional de Supercomputación (BSC-CNS), applies cutting-edge artificial intelligence (AI) technologies to predict and prevent strokes, one of the leading causes of death and disability worldwide.

Its flagship product, INVICTUS, is an AI-based platform compatible with standard electrocardiogram (ECG) devices and wearables, which identifies stroke risk through pattern recognition in ECG readings. The technology is built on the GALEN model, a proprietary AI capable of detecting disease-associated biomarkers without invasive testing such as genetic sequencing or protein analysis.

This breakthrough marks a revolution in preventive medicine by replacing costly and complex methods with a scalable, consumer-device-friendly solution. OneCareAI’s technology also significantly reduces healthcare expenditure linked to the prevention, detection, and treatment of strokes, which currently amounts to nearly $1 trillion annually, with 12.2 million new stroke cases each year.

Moreover, beyond strokes, GALEN’s applications extend to cardiovascular, neurological, respiratory, and metabolic diseases, opening up further growth opportunities.

Albert Mascarell, Director of MWCapital’s technology transfer area, affirmed that: “Projects like OneCareAI show the power of science and research in delivering solutions that address market needs and improve people’s quality of life.”

“The creation of OneCareAI represents a key step in bringing this technology, developed at BSC, to patients. The tool has been developed using advanced supercomputing and AI to optimise non-invasive stroke prevention and monitoring,” said Mariona Sanz, Head of Innovation and Business Development at BSC.

Technology validation and innovation support

OneCareAI joined the 8th edition of MWCapital’s Opportunity Validation programme, where it validated its market potential and feasibility proposal. It later took part in the 8th edition of the Business Validation programme, focusing on growth strategy, business model, and access to the European healthcare market.

The project was founded by a team with strong expertise in technology, healthcare, and entrepreneurship: Xavier Guillem (CEO), Daniele Lezzi (CTO), and Davide Cirillo (CSO), all with proven experience in biomedical AI and technological integration in regulated environments.

Ongoing support for technology transfer

Currently, 95% of European patents never reach the market. MWCapital’s technology transfer programme is committed to identifying innovations from universities and research centres and helping them transition into industrial solutions that reach society.

Since its inception eight years ago, MWCapital’s technology transfer programme has supported more than 200 research projects; has driven the creation of 22 spin-offs, generating over 170 jobs; and currently maintains a portfolio of 13 companies across sectors including energy and sustainability, health, and industrial and logistics solutions, with a combined valuation of over €100 million.